A Study of HR19024 in Subjects With Advanced Solid Tumor
To evaluate the safety，tolerability，pharmacokinetic characteristics and preliminary efficacy of HR19024 injection in the treatment of advanced solid tumor
Advanced Solid Tumor
DRUG: HR19024
Maximum tolerated dose (MTD) of HR19024, 21-day cycle (tri-weekly)
Response rate (RR), up to 6 months following the date the last patient was randomized|Disease Control Rate, up to 6 months following the date the last patient was randomized|Duration of Response, up to 6 months following the date the last patient was randomized|Progression free survival (PFS), up to 6 months following the date the last patient was randomized
To evaluate the safety，tolerability，pharmacokinetic characteristics and preliminary efficacy of HR19024 injection in the treatment of advanced solid tumor